W. D. Travis, E. Brambilla, A. G. Nicholson, Y. Yatabe, J. Austin et al., The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification, J Thorac Oncol, vol.10, pp.1243-60, 2015.

J. N. Spaans and G. D. Goss, Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer, Front Oncol, vol.4, p.190, 2014.

M. Malumbres and M. Barbacid, Mammalian cyclin-dependent kinases, Trends Biochem Sci, vol.30, pp.630-671, 2005.

M. Malumbres, E. Harlow, T. Hunt, T. Hunter, J. M. Lahti et al., Cyclin-dependent kinases: a family portrait, Nat Cell Biol, vol.11, pp.1275-1281, 2009.

E. A. Musgrove, C. E. Caldon, J. Barraclough, A. Stone, and R. L. Sutherland, Cyclin D as a therapeutic target in cancer, Nat Rev Cancer, vol.11, pp.558-72, 2011.

O. Gautschi, D. Ratschiller, M. Gugger, D. C. Betticher, and J. Heighway, Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation, Lung Cancer, vol.55, pp.1-14, 2007.

Y. Dobashi, A. Goto, M. Fukayama, A. Abe, and A. Ooi, Overexpression of cdk4/cyclin D1, a possible mediator of apoptosis and an indicator of prognosis in human primary lung carcinoma, Int J Cancer, vol.110, pp.532-573, 2004.

M. Puyol, A. Martin, P. Dubus, F. Mulero, P. Pizcueta et al., A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma, Cancer Cell, vol.18, pp.63-73, 2010.

U. Asghar, A. K. Witkiewicz, N. C. Turner, and E. S. Knudsen, The history and future of targeting cyclin-dependent kinases in cancer therapy, Nat Rev Drug Discov, vol.14, pp.130-176, 2015.

M. Peyressatre, C. Prevel, M. Pellerano, and M. C. Morris, Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors, Cancers (Basel), vol.7, pp.179-237, 2015.

S. Lapenna and A. Giordano, Cell cycle kinases as therapeutic targets for cancer, Nat Rev Drug Discov, vol.8, pp.547-66, 2009.

D. Cirillo, F. Pentimalli, and A. Giordano, Peptides or small molecules? Different approaches to develop more effective CDK inhibitors, Curr Med Chem, vol.18, pp.2854-66, 2011.

A. A. Abate, F. Pentimalli, L. Esposito, and A. Giordano, ATP-noncompetitive CDK inhibitors for cancer therapy: an overview, Expert Opin Investig Drugs, vol.22, pp.895-906, 2013.

C. Bruyere and L. Meijer, Targeting cyclin-dependent kinases in anti-neoplastic therapy, Curr Opin Cell Biol, vol.25, pp.772-781, 2013.

M. A. Dickson, Molecular pathways: CDK4 inhibitors for cancer therapy, Clin Cancer Res, vol.20, pp.3379-83, 2014.

P. J. Roberts, J. E. Bisi, J. C. Strum, A. J. Combest, D. B. Darr et al., Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy, J Natl Cancer Inst, vol.104, pp.476-87, 2012.

A. Patnaik, L. S. Rosen, S. M. Tolaney, A. W. Tolcher, J. W. Goldman et al., Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors, Cancer Discov, vol.6, pp.740-53, 2016.

M. T. Herrera-abreu, M. Palafox, U. Asghar, M. A. Rivas, R. J. Cutts et al., Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer, Cancer Res, vol.76, pp.2301-2314, 2016.

P. Wu, T. E. Nielsen, and M. H. Clausen, Small-molecule kinase inhibitors: an analysis of FDA-approved drugs, Drug Discov Today, vol.21, pp.5-10, 2016.

E. Haines, T. Chen, N. Kommajosyula, Z. Chen, G. S. Herter-sprie et al., Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer, Oncotarget, vol.9, pp.31572-89, 2018.

A. J. Wilson, Inhibition of protein-protein interactions using designed molecules, Chem Soc Rev, vol.38, pp.3289-300, 2009.

D. E. Scott, A. R. Bayly, C. Abell, and J. Skidmore, Small molecules, big targets: drug discovery faces the protein-protein interaction challenge, Nat Rev Drug Discov, vol.15, pp.533-50, 2016.

L. D. Walensky, A. L. Kung, I. Escher, T. J. Malia, S. Barbuto et al., Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix, Science, vol.305, pp.1466-70, 2004.

L. D. Walensky, K. Pitter, J. Morash, K. J. Oh, S. Barbuto et al., A stapled BID BH3 helix directly binds and activates BAX, Mol Cell, vol.24, pp.199-210, 2006.

H. Zhang, Q. Zhao, S. Bhattacharya, A. A. Waheed, X. Tong et al., A cell-penetrating helical peptide as a potential HIV-1 inhibitor, J Mol Biol, vol.378, pp.565-80, 2008.

F. Bernal, A. F. Tyler, S. J. Korsmeyer, L. D. Walensky, and G. L. Verdine, Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide, J Am Chem Soc, vol.129, pp.2456-2463, 2007.

R. E. Moellering, M. Cornejo, T. N. Davis, D. Bianco, C. Aster et al., Direct inhibition of the NOTCH transcription factor complex, Nature, vol.462, pp.182-190, 2009.

F. Meric-berntam, M. N. Saleh, J. R. Infante, S. Goel, G. S. Falchook et al., Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX-and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas, Journal of Clinical Oncology, vol.35, p.2505, 2017.

M. Payton, D. Pinchasik, A. Mehta, S. Goel, J. M. Zain et al., Phase 2a study of a novel stapled peptide ALRN-6924 disrupting MDMX-and MDM2-mediated inhibition of wild-type TP53 in patients with peripheral t-cell lymphoma, Ann Oncol, vol.28, pp.355-71, 2017.

P. D. Jeffrey, A. A. Russo, K. Polyak, E. Gibbs, J. Hurwitz et al., Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex, Nature, vol.376, pp.313-333, 1995.

M. C. Morris, C. Gondeau, J. A. Tainer, and G. Divita, Kinetic mechanism of activation of the Cdk2/cyclin A complex. Key role of the C-lobe of the Cdk, J Biol Chem, vol.277, pp.23847-53, 2002.

C. Gondeau, S. Gerbal-chaloin, P. Bello, G. Aldrian-herrada, M. C. Morris et al., Design of a novel class of peptide inhibitors of cyclin-dependent kinase/cyclin activation, J Biol Chem, vol.280, pp.13793-800, 2005.

G. R. Ferretti, B. Busser, F. De-fraipont, E. Reymond, A. Mcleer-florin et al., Adequacy of CT-guided biopsies with histomolecular subtyping of pulmonary adenocarcinomas: influence of ATS/ERS/IASLC guidelines, Lung Cancer, vol.82, pp.69-75, 2013.

B. Busser, M. T. Leccia, G. Gras-combe, I. Bricault, I. Templier et al., Identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma, JAMA Dermatol, vol.149, pp.1403-1409, 2013.

A. Hurbin, M. Wislez, B. Busser, M. Antoine, C. Tenaud et al., Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma, The Journal of pathology, vol.225, pp.83-95, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00598462

S. J. Miller and R. H. Grubbs, Synthesis of conformationally restricted amino acids and peptides employing olefin matathesis, J Am Chem Soc, vol.117, pp.5855-5861, 1995.

S. J. Miller, H. E. Blackwell, and R. H. Grubbs, Application of ring-closing metathesis to the synthesis of rigidified amino acids and peptides, J Am Chem Soc, vol.118, pp.9606-9620, 1996.

H. E. Blackwell and R. H. Grubbs, Highly Efficient Synthesis of Covalently Cross-Linked Peptide Helices by Ring-Closing Metathesis, Angew Chem Int Ed Engl, vol.37, pp.3281-3285, 1998.

Q. Chu, R. E. Moellering, G. J. Hilinski, Y. W. Kim, T. N. Grossmann et al., Towards understanding cell pemetration by stapled peptides, Med Chem Commun, vol.6, pp.111-120, 2015.

L. D. Walensky and G. H. Bird, Hydrocarbon-stapled peptides: principles, practice, and progress, J Med Chem, vol.57, pp.6275-88, 2014.

G. H. Bird, F. Bernal, K. Pitter, and L. D. Walensky, Synthesis and biophysical characterization of stabilized alpha-helices of BCL-2 domains, Methods Enzymol, vol.446, pp.369-86, 2008.

C. E. Schafmeister, J. Po, and G. L. Verdine, An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides, J Am Chem Soc, vol.122, pp.5891-5893, 2000.

G. L. Verdine and G. J. Hilinski, Stapled peptides for intracellular drug targets, Methods Enzymol, vol.503, pp.3-33, 2012.

M. Pellerano, D. Naud-martin, M. Peyressatre, C. Prevel, M. P. Teulade-fichou et al., TP-2Rho Is a Sensitive Solvatochromic Red-Shifted Probe for Monitoring the Interactions between CDK4 and Cyclin D, Chembiochem, vol.17, pp.737-781, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02009852

C. Prevel, M. Pellerano, J. A. Gonzalez-vera, H. P. Meunier, L. Vollaire et al., Fluorescent peptide biosensor for monitoring CDK4/cyclin D kinase activity in melanoma cell extracts, mouse xenografts and skin biopsies, Biosens Bioelectron, vol.85, pp.371-80, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01905259

M. Pellerano, D. Naud-martin, F. Mahuteau-betzer, M. Morille, and M. C. Morris, Fluorescent Biosensor for Detection of the R248Q
URL : https://hal.archives-ouvertes.fr/hal-02009856

, Aggregation-Prone Mutant of p53, Chembiochem, vol.20, pp.605-618, 2019.

V. Jeannot, C. Gauche, S. Mazzaferro, M. Couvet, L. Vanwonterghem et al., Anti-tumor efficacy of hyaluronan-based nanoparticles for the co-delivery of drugs in lung cancer, Journal of controlled release : official journal of the Controlled Release Society, vol.275, pp.117-145, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02151669

V. Jeannot, S. Mazzaferro, J. Lavaud, L. Vanwonterghem, M. Henry et al., Targeting CD44 receptor-positive lung tumors using polysaccharide-based nanocarriers: Influence of nanoparticle size and administration route, Nanomedicine, vol.12, pp.921-953, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01360462

A. Koenig, L. Herve, V. Josserand, M. Berger, J. Boutet et al., In vivo mice lung tumor follow-up with fluorescence diffuse optical tomography, J Biomed Opt, vol.13, p.11008, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00313764

C. H. Wenk, F. Ponce, S. Guillermet, C. Tenaud, D. Boturyn et al., Near-infrared optical guided surgery of highly infiltrative fibrosarcomas in cats using an anti-alphavss3 integrin molecular probe, Cancer Lett, vol.334, pp.188-95, 2013.

P. J. Day, A. Cleasby, I. J. Tickle, M. O'reilly, J. E. Coyle et al., Crystal structure of human CDK4 in complex with a D-type cyclin, Proc Natl Acad Sci, vol.106, pp.4166-70, 2009.

D. M. Kruger and H. Gohlke, DrugScorePPI webserver: fast and accurate in silico alanine scanning for scoring protein-protein interactions, Nucleic Acids Res, vol.38, pp.480-486, 2010.

M. Malumbres and M. Barbacid, Cell cycle kinases in cancer, Curr Opin Genet Dev, vol.17, pp.60-65, 2007.

M. Malumbres and M. Barbacid, Cell cycle, CDKs and cancer: a changing paradigm, Nat Rev Cancer, vol.9, pp.153-66, 2009.

T. Vanarsdale, C. Boshoff, K. T. Arndt, and R. T. Abraham, Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment, Clin Cancer Res, vol.21, pp.2905-2915, 2015.

L. M. Gelbert, S. Cai, X. Lin, C. Sanchez-martinez, D. Prado et al., Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine, Invest New Drugs, vol.32, pp.825-862, 2014.

J. W. Goldman, P. Shi, M. Reck, L. Paz-ares, A. Koustenis et al., Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy, Clin Lung Cancer, vol.17, pp.80-84, 2016.

N. Vidula and H. S. Rugo, Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data, Clin Breast Cancer, vol.16, pp.8-17, 2016.

V. Azzarito, K. Long, N. S. Murphy, and A. J. Wilson, Inhibition of alpha-helix-mediated protein-protein interactions using designed molecules, Nat Chem, vol.5, pp.161-73, 2013.

N. S. Robertson and D. R. Spring, Using Peptidomimetics and Constrained Peptides as Valuable Tools for Inhibiting Protein(-)Protein Interactions, Molecules, p.23, 2018.

S. Dufort, A. Bianchi, M. Henry, F. Lux, L. Duc et al., Nebulized Gadolinium-Based Nanoparticles: A Theranostic Approach for Lung Tumor Imaging and Radiosensitization, Small, vol.11, pp.215-236, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01115895

L. Guilleminault, N. Azzopardi, C. Arnoult, J. Sobilo, V. Herve et al., Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system, Journal of controlled release : official journal of the Controlled Release Society, vol.196, pp.344-54, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02376374

J. Jia, F. Zhu, X. Ma, Z. Cao, Z. W. Cao et al., Mechanisms of drug combinations: interaction and network perspectives, Nat Rev Drug Discov, vol.8, pp.111-139, 2009.

M. Malumbres, CDK4/6 Inhibitors: What Is the Best Cocktail?, Clin Cancer Res, vol.25, pp.6-8, 2019.

H. Chen, X. Xu, G. Wang, B. Zhang, G. Wang et al., CDK4 protein is degraded by anaphase-promoting complex/cyclosome in mitosis and reaccumulates in early G1 phase to initiate a new cell cycle in HeLa cells, J Biol Chem, vol.292, pp.10131-10172, 2017.